文献速递性腺与生殖内分泌

年轻男性滥用雄激素的临床管理:以减害为策略

Approach to the Young Male Patient Who Abuses Androgens: Harm Reduction as a Clinical Strategy.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本文针对年轻男性非医疗使用雄激素的临床管理提出框架,强调非评判性诊断和两条并行管理策略:对有意停药者提供结构化监测与心理支持,至少12个月戒断后持续生化性性腺功能减退伴症状才考虑睾酮替代;对不愿停药者采用减害方法,包括剂量降低、化合物选择、周期结构和心血管风险管理。

要点

  • 采用非评判性诊断方法,避免将戒断作为就医前提。
  • 有意停药者:结构化监测和心理支持,至少12个月戒断后评估是否需睾酮替代。
  • 不愿停药者:减害策略包括剂量降低、化合物选择、周期结构和心血管风险管理。

核心结论

  • 对年轻男性雄激素滥用者应提供非评判性诊断和并行的停药支持与减害策略。
  • 仅当至少12个月戒断后持续存在生化性性腺功能减退伴症状时,才按标准指南考虑睾酮替代治疗。

研究设计与样本

  • 本文为临床方法学文章,基于广泛临床经验提出管理框架,未报告系统检索或样本量。

主要发现

  • 临床中年轻男性非医疗使用雄激素日益常见,尤其见于力量训练者。
  • 许多使用者出现雄激素相关主诉或并发症,但因医生不熟悉、污名化或要求戒断作为就医条件而获得有限医疗支持。

关键数值与推荐

  • 对有意停药者:结构化监测和心理支持以促进激素恢复和降低复发风险。
  • 仅当至少12个月戒断后持续生化性性腺功能减退伴症状时,才按标准指南考虑睾酮替代治疗。
  • 对不愿或尚未准备停药者:减害建议包括剂量降低、化合物选择、周期结构和心血管风险管理。

临床怎么用

  • 临床应主动接纳雄激素滥用者,不以戒断为就医前提,提供非评判性诊断。
  • 根据患者停药意愿分流:支持停药或提供减害建议,以缩小临床照护与使用者行为之间的差距。

局限性

  • 本文基于广泛临床经验提出建议,未报告系统检索、样本量或定量结局数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nonmedical use of androgens is increasingly encountered in clinical practice, particularly among young men engaging in strength training. Many present with androgen-related complaints or complications but receive limited medical support because of clinician unfamiliarity, stigma, or the perceived need for abstinence as a condition for care. This article outlines a framework for engaging with androgen abusers in clinical practice, emphasizing a nonjudgmental diagnostic approach and 2 parallel management strategies. For individuals motivated to discontinue, structured monitoring and psychological support are key to facilitating hormonal recovery and reducing relapse risk. Only in cases where biochemical hypogonadism with symptoms persists after at least 12 months of abstinence should testosterone replacement therapy be considered in line with standard guidelines. For those unwilling or not yet ready to stop, a harm reduction approach is proposed. Drawing on extensive clinical experience, we provide recommendations for minimizing health risks, including dose reduction, compound selection, cycle structuring, and cardiovascular risk management. This dual strategy-supporting cessation where possible while mitigating harm where possible-offers a realistic and ethical response to the growing population of androgen abusers and aims to bridge the current gap between clinical care and user behavior.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Smit DL, Verdegaal T, Bond P, et al. Approach to the Young Male Patient Who Abuses Androgens: Harm Reduction as a Clinical Strategy. J Clin Endocrinol Metab. 2025. PMID: 40908538. doi:10.1210/clinem/dgaf496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。